Talis Biomedical Corporation

    Talis Biomedical Corporation

    OOTC:TLIS
    2.84
    USD
    0.00
    (0.00%)
    Talis Biomedical Corporation
    OTC:TLIS
    (OTC Markets)

    Recent

    price

    2.84

    P/E

    ratio

    - -

    div

    yld

    - -

    ROIC.AI

    2018
    2019
    2020
    2021
    2022
    2023
    TTM
    USD
    - -
    - -
    - -
    - -
    2.04
    0.23
    0.16
    Revenue per Share
    -141.85
    -94.51
    -69.46
    -109.08
    -63.26
    -34.12
    -28.02
    Basic EPS, GAAP
    -142.77
    -85.67
    -72.58
    -98.98
    -56.96
    -29.56
    -22.09
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    -361
    -281.32
    -131.79
    -207.29
    -267.55
    -297.09
    -308.51
    Book Value per Share
    -345.71
    -72.72
    -82.75
    132.9
    70.95
    38.03
    26.7
    Tangible Book Value per Share
    - -
    - -
    1
    2
    2
    2
    2
    Basic Weighted Avg Shares
    - -
    - -
    - -
    - -
    4
    - -
    - -
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    -3,152.77
    -16,217.23
    -18,374
    Operating Margin (%)
    1
    1
    1
    2
    9
    1
    1
    Depreciation Expense
    -21
    -27
    -91
    -192
    -113
    -62
    -51
    Net Income, GAAP
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    -3,094.52
    -15,050.24
    -17,008.67
    Profit Margin (%)
    6
    20
    173
    217
    121
    69
    55
    Working Capital
    - -
    - -
    - -
    13
    30
    17
    16
    LT Debt
    -52
    -21
    -109
    234
    127
    69
    49
    Total Equity
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)

    Capital Structure

    USD

    •

    in mil. unless spec.
    Dec'23
    Mar'24
    Jun'24
    ST Debt
    3
    3
    3
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    17
    16
    16
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    2
    2
    2
    Market Capitalization
    14
    16
    16

    Working Capital

    USD

    •

    in mil. unless spec.
    Dec'23
    Mar'24
    Jun'24
    Total Current Assets
    78
    71
    64
    Cash, Cash Equivalents & STI
    77
    70
    60
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    9
    9
    8
    Payables & Accruals
    2
    5
    4
    ST Debt
    3
    3
    3
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    -10.52%
    -45.47%
    Free Cash Flow
    - -
    58.5%
    -47.2%
    Net Income, GAAP
    - -
    56.98%
    -45.13%
    Sales/Revenue/Turnover
    - -
    - -
    -88.72%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    2
    1
    1
    - -
    4
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    -18.73
    -15.01
    -14.44
    -15.07
    -63.26
    2023
    -9.84
    -8.27
    -8.62
    - -
    -34.12
    2024
    -7.15
    -4.86
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • defenseworld.net

      Talis Biomedical (NASDAQ:TLIS) Shares Up 77.5% – Still a Buy?

    • https://www.marketscreener.com

      North American Morning Briefing : Global Ad Shares -2-

    • investorplace.com

      Why Is Talis Biomedical (TLIS) Stock Down 52% Today?

    • globenewswire.com

      Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash

    • investorplace.com

      7 Small-Cap Stocks to Sell in August Before They Crash and Burn

    • seekingalpha.com

      Talis Biomedical Corporation (TLIS) Q2 2023 Earnings Call Transcript

    • globenewswire.com

      Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update

    • globenewswire.com

      Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023

    • globenewswire.com

      Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)

    • globenewswire.com

      Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement

    • seekingalpha.com

      Talis Biomedical Corporation (TLIS) Q1 2023 Earnings Call Transcript

    • globenewswire.com

      Talis Biomedical to Provide Business Update and Financial Results on May 11, 2023

    • globenewswire.com

      Press release Biocartis Group NV: Biocartis appoints Roger Moody as new CEO

    • seekingalpha.com

      Talis Biomedical Corporation (TLIS) CEO Rob Kelly on Q2 2022 Results - Earnings Call Transcript

    • seekingalpha.com

      Talis Biomedical Corporation(TLIS) CEO Rob Kelly on Q12022 Results - Earnings Call Transcript

    • globenewswire.com

      Talis Biomedical to Announce First Quarter 2022 Financial Results on May 10, 2022

    • marketwatch.com

      Talis Biomedical stock bounces off record low after largest shareholder pulls share-sale plans

    • seekingalpha.com

      Talis Biomedical Corporation (TLIS) CEO Rob Kelly on Q4 2021 Results - Earnings Call Transcript

    • seekingalpha.com

      Talis Biomedical Corporation (TLIS) CEO Kim Popovits on Q3 2021 Results - Earnings Call Transcript

    • pulse2.com

      Talis Biomedical (TLIS) Stock: Why The Price Surged Today